NASDAQ:ASRT

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 28, 2024
Rheumatoid arthritis, Learning, EPS, Risk, Telephone, Patient, Suppository, Sale, Acquisition, News, ASRT, Complaint, Adjustment, P.C, Spectrum, Spectrum Pharmaceuticals, FDA, Food, Cryptocurrency

Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • Then, on November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter ("Q3") of 2023.

ASRT SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Thursday, February 29, 2024
Acquisition, Court, Person, FDA, News, Fraud, CFTC, District court, Adjustment, Lead, Q3, Suppository, Medicare, IRS, LLP, EPS, COPY, Cryptocurrency

Radnor, Pennsylvania--(Newsfile Corp. - February 29, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been against Assertio Holdings, Inc. ("Assertio") (NASDAQ: ASRT).

Key Points: 
  • Radnor, Pennsylvania--(Newsfile Corp. - February 29, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been against Assertio Holdings, Inc. ("Assertio") (NASDAQ: ASRT).
  • The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.
  • As a result of Assertio' s materially misleading statements and omissions to the public, Assertio' s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Assertio investors who have suffered significant losses to contact the firm directly to acquire more information.

March 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ASRT

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, Court, NEXT, Telephone, COST, Sale, Risk, CLASS, Spectrum Pharmaceuticals, LLP, ASRT, Cryptocurrency

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    ASRT investors may also contact Joseph E. Levi, Esq.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

DEADLINE ALERT for ASRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Tuesday, March 5, 2024
Suite, Spectrum, Investment, Sale, Risk, Law, Defendant, Security (finance)

LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Monday, March 4, 2024
Acquisition, FDA, News, Food, Zydus Lifesciences, Suppository, ASRT

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Assertio stock. Assertio investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ​ The Portnoy Law Firm advises Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Assertio stock.
  • Assertio investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

DEADLINE TOMORROW: Berger Montague Advises Assertio Holdings (NASDAQ: ASRT) Investors to Inquire About a Securities Fraud Class Action by March 5, 2024

Retrieved on: 
Monday, March 4, 2024
Attention, Court, FDA, News, Food, Lead, Rheumatoid arthritis, Patient, ASRT, The, Cryptocurrency

A securities fraud class action lawsuit has been filed against Assertio on behalf of purchasers of Assertio’s securities between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • A securities fraud class action lawsuit has been filed against Assertio on behalf of purchasers of Assertio’s securities between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”).
  • Important deadline: Investors who purchased or acquired Assertio securities during the Class Period may, no later than March 5, 2024, seek to be appointed as a lead plaintiff representative of the class.
  • Berger Montague , with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970.
  • Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

ASRT CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Monday, March 4, 2024
Acquisition, Court, Person, FDA, News, Fraud, CFTC, District court, Adjustment, Lead, Q3, Suppository, Medicare, IRS, LLP, EPS, COPY

The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Assertio’ s materially misleading statements and omissions to the public, Assertio’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Assertio investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against Assertio, Shapiro v. Assertio Holdings, Inc., et al., Case No.

FINAL ASRT SHAREHOLDER DEADLINE: Bronstein, Gewirtz & Grossman LLC Announces that Assertio Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, March 4, 2024
Court, Person, Spectrum, Sale, Complaint, Risk

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ASRT .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ASRT .
  • The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ASSERTIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Assertio Holdings, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024
Complaint, Acquisition, Court, Person, Spectrum, Telephone, FDA, News, Food, Sale, District court, Learning, Adjustment, Risk, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, EPS, P.C, Cryptocurrency

Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Friday, March 1, 2024
GPM, Acquisition, Court, Suite, Spectrum, News, Food, Sale, Risk, Suppository, ASRT, Defendant, Cryptocurrency

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Assertio’s stock price fell $2.44, or 45.6%, to close at $2.91 per share on August 4, 2023, thereby injuring investors.
  • Then, on January 3, 2024, Assertio announced that its CEO was stepping down from his role at the Company.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.